DAN LENDER
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- ROCKWALL, TX
- NPI
- 1760445274
- Received
- $83,245 in 290 records, 2019 to 2025 ($10,019 general, $73,226 research)
- As principal investigator
- $2,556,222 of research payments to others in 120 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $27 |
| 2024 | General payment | 24 | $870 |
| 2024 | Research payment | 5 | $73,196 |
| 2023 | General payment | 34 | $1,193 |
| 2023 | Research payment | 1 | $30 |
| 2022 | General payment | 55 | $874 |
| 2021 | General payment | 60 | $1,058 |
| 2020 | General payment | 47 | $889 |
| 2019 | General payment | 62 | $5,104 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $73,226 |
| Food and Beverage | 251 | $5,052 |
| Travel and Lodging | 26 | $3,233 |
| Consulting Fee | 1 | $1,485 |
| Education | 4 | $129 |
| Gift | 2 | $118 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-03 | BETA BIONICS, INC. | $9 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-03-04 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | PROCLAIM Device, Structural Heart | 2025 | |
| 2024-09-27 | Eli Lilly and Company | $5,606 | Research payment | Cash or cash equivalent | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $41,090 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $12,263 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $9,957 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $4,280 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2024-09-20 | AstraZeneca Pharmaceuticals LP | $51 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-09-11 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-18 | Eli Lilly and Company | $169 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $98 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $85 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $71 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $56 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $31 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $21 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $5 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $5 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $4 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $1 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $0 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-05-23 | Medtronic, Inc. | $18 | Food and Beverage | In-kind items and services | VENASEAL Device, EndoVenous Therapies | 2024 | |
| 2023-09-29 | Eli Lilly and Company | $30 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-09-11 | Eli Lilly and Company | $441 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-11 | Eli Lilly and Company | $159 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-09-11 | Eli Lilly and Company | $18 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-08-17 | Nevro Corp. | $16 | Food and Beverage | In-kind items and services | Senza Device, Spinal Cord Stimulator | 2023 | |
| 2023-08-01 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-07-26 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-07-23 | Abbott Laboratories | $38 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-06-14 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-06-13 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-06-07 | Mannkind Corporation | $14 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-05-23 | Dexcom, Inc. | $26 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-05-23 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-05-16 | Medtronic, Inc. | $16 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2023 | |
| 2023-05-10 | Alexion Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2023 | |
| 2023-05-03 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-05-02 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2023 | |
| 2023-05-02 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-05-02 | Dexcom, Inc. | $6 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-04-27 | Embecta Corp. | $20 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-04-20 | Mannkind Corporation | $21 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-04-17 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-04-11 | Embecta Corp. | $24 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-04-05 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-04-04 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-03-28 | Mannkind Corporation | $17 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-03-23 | Alexion Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2023 | |
| 2023-03-15 | Dexcom, Inc. | $18 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-03-10 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-03-01 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2023 | |
| 2023-02-22 | Dexcom, Inc. | $19 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-02-09 | Mannkind Corporation | $14 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-02-09 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-01-30 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-01-20 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2022-12-23 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-12-14 | Mannkind Corporation | $12 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-12-06 | Xeris Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2022-12-05 | Mannkind Corporation | $8 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-11-17 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-11-16 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-11-16 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-11-09 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-11-03 | Mannkind Corporation | $12 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-11-02 | Dexcom, Inc. | $26 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-11-02 | Dexcom, Inc. | $26 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-11-01 | Antares Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2022 | |
| 2022-10-20 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-10-03 | Dexcom, Inc. | $23 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-09-29 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-09-28 | Dexcom, Inc. | $18 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-09-20 | Xeris Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2022-09-16 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-09-14 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-09-12 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-09-07 | Mannkind Corporation | $18 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-09-01 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-08-31 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2022 | |
| 2022-08-18 | Mannkind Corporation | $20 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-08-04 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-08-03 | Alexion Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2022 | |
| 2022-07-27 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-07-11 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-06-30 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-06-29 | CeQur Corporation | $3 | Food and Beverage | Cash or cash equivalent | CeQur Simplicity Device, Diabetes | 2022 | |
| 2022-06-22 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-06-14 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-06-09 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2022 | |
| 2022-06-09 | Mannkind Corporation | $7 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-06-08 | Mannkind Corporation | $2 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-05-25 | Dexcom, Inc. | $9 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-05-19 | Mannkind Corporation | $18 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-05-18 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2022 | |
| 2022-05-09 | Insulet Corporation | $19 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2022 | |
| 2022-05-04 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-04-27 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-04-13 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-04-07 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-30 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-03-28 | Amarin Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2022 | |
| 2022-03-23 | Dexcom, Inc. | $12 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-03-16 | Amneal Pharmaceuticals LLC | $11 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2022 | |
| 2022-03-03 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2022 | |
| 2022-03-02 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-03-02 | Mannkind Corporation | $12 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-02-17 | Ascensia Diabetes Care Us Inc. | $18 | Food and Beverage | In-kind items and services | EVERSENSE E3 SMART TRANSMITTER KIT Device, TRANSMITTER KIT | 2022 | |
| 2022-02-08 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-02-02 | Mannkind Corporation | $15 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2022 | |
| 2022-01-26 | Dexcom, Inc. | $19 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-01-12 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2021-12-29 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2021 | |
| 2021-12-15 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-12-13 | Ascensia Diabetes Care Us Inc. | $20 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-12-08 | Mannkind Corporation | $59 | Gift | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2021 | |
| 2021-12-02 | Abbott Laboratories | $13 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-11-30 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2021 | |
| 2021-11-24 | Mannkind Corporation | $9 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2021 | |
| 2021-11-23 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2021 | |
| 2021-11-17 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-11-01 | Xeris Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, DIABETES | 2021 | |
| 2021-10-28 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-10-27 | Amarin Pharma, Inc. | $20 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-10-13 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-10-07 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-10-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-09-29 | Dexcom, Inc. | $16 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-09-15 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-09-03 | Amarin Pharma, Inc. | $1 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-08-26 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FreeStyle Libre Device, Diabetes Care | 2021 | |
| 2021-08-25 | Amneal Pharmaceuticals LLC | $29 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2021 | |
| 2021-08-16 | Zealand Pharma US, Inc. | $13 | Food and Beverage | In-kind items and services | ZEGALOGUE Drug, 1 | 2021 | |
| 2021-08-04 | Dexcom, Inc. | $16 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-08-04 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-07-29 | Zealand Pharma US, Inc. | $26 | Food and Beverage | In-kind items and services | V-GO DISPOSABLE INSULIN DELIVERY Device, 1 | 2021 | |
| 2021-07-27 | Zealand Pharma US, Inc. | $21 | Food and Beverage | In-kind items and services | V-GO DISPOSABLE INSULIN DELIVERY Device, 1 | 2021 | |
| 2021-07-16 | Amarin Pharma, Inc. | $7 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-07-15 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-06-28 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-17 | Ascensia Diabetes Care Us Inc. | $14 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-06-14 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-14 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-14 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-14 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-11 | Amarin Pharma, Inc. | $8 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-06-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-05-27 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2021 | |
| 2021-05-25 | Amarin Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-21 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2021 | |
| 2021-05-21 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2021 | |
| 2021-05-14 | Amarin Pharma, Inc. | $5 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-12 | Radius Health, Inc. | $19 | Food and Beverage | In-kind items and services | Tymlos Biological, Endocrinology | 2021 | |
| 2021-05-05 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2021 | |
| 2021-05-03 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2021 | |
| 2021-04-29 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-04-15 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2021 | |
| 2021-04-07 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2021 | |
| 2021-04-02 | Mannkind Corporation | $11 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2021 | |
| 2021-03-11 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-04 | Amarin Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-03-04 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2021 | |
| 2021-03-02 | Amarin Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-02-15 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | HUMULIN Drug, Diabetes | 2021 | |
| 2021-02-09 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-02-04 | Amarin Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-01-28 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | Tirosint Drug, Endocrinology | 2021 | |
| 2021-01-26 | GRT US Holding, Inc. | $13 | Food and Beverage | In-kind items and services | Qutenza Drug, Pain Management | 2021 | |
| 2021-01-25 | Amarin Pharma, Inc. | $24 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-01-21 | Mannkind Corporation | $24 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2021 | |
| 2021-01-07 | Amarin Pharma, Inc. | $18 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-01-06 | Dexcom, Inc. | $23 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2020-12-11 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2020 | |
| 2020-12-10 | Mannkind Corporation | $19 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2020 | |
| 2020-12-01 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FreeStyle Libre Device, Diabetes Care | 2020 | |
| 2020-11-20 | Acerus Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | Natesto Drug, Urology Endocrinology Men's Health | 2020 | |
| 2020-11-19 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2020 | |
| 2020-11-12 | Mannkind Corporation | $11 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2020 | |
| 2020-10-28 | Amarin Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-10-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-10-15 | Medtronic MiniMed, Inc. | $15 | Food and Beverage | In-kind items and services | InPen Device, Continuous Glucose Monitoring | 2020 | |
| 2020-10-14 | Radius Health, Inc. | $18 | Food and Beverage | In-kind items and services | Tymlos Biological, Endocrinology | 2020 | |
| 2020-10-05 | Amarin Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-10-01 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-09-23 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2020 | |
| 2020-09-14 | Merck Sharp & Dohme LLC | $12 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-09-10 | Mannkind Corporation | $14 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2020 | |
| 2020-09-08 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2020 | |
| 2020-09-01 | Amarin Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-08-27 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2020 | |
| 2020-08-26 | Amarin Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 |
The latest 200 records of 290.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-26 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $18,134 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-12-19 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $1,734 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-12-19 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $16,203 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM | 2025 |
| 2025-12-19 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $5,253 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-12-15 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $27,321 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT REDUCTION WITH MACUPATIDE AND EL | 2025 |
| 2025-12-04 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $26,588 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-12-04 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $22,644 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM | 2025 |
| 2025-11-26 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $800 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-11-20 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $5,365 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-11-14 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $6,388 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-11-14 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $12,572 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-11-14 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $6,247 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-11-06 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $3,468 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-10-24 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $7,437 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-10-16 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $7,529 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-10-09 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $30,328 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-10-09 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $21,205 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-10-09 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $183 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-09-24 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $13,863 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $4 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $365 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-09-11 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $7,877 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-09-11 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $1,211 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PART | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $19 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $292 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-08-26 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $14,349 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-08-21 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $12,572 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-08-21 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $14,500 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-08-21 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $2,400 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-08-21 | VERTEX PHARMACEUTICALS INCORPORATED | VELOCITY CLINICAL RESEARCH DALLAS | $1,610 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine | 2025 |
| 2025-08-21 | Hoffmann-La Roche Limited | VELOCITY CLINICAL RESEARCH INC | $1,500 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-08-14 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $6,015 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-07-31 | Eli Lilly and Company | DALLAS DIABETES AND ENDO RESEARCH CENTER PA | $105 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-07-31 | Eli Lilly and Company | DALLAS DIABETES AND ENDO RESEARCH CENTER PA | $105 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-07-31 | Eli Lilly and Company | DALLAS DIABETES AND ENDO RESEARCH CENTER PA | $105 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-07-23 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $11,801 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-07-17 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $2,400 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-07-16 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $1,112 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-07-10 | Genentech, Inc. | VELOCITY CLINICAL RESEARCH INC | $9,445 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $36 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $19 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-06-19 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $6,599 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-06-11 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $10,775 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-06-09 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $307,679 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PART | 2025 |
| 2025-05-26 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $3,504 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-05-05 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $19,001 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND L | 2025 |
| 2025-05-05 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $867 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-05-05 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $23,942 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO | 2025 |
| 2025-04-29 | Amgen Inc. | VELOCITY CLINICAL RESEARCH - DALLAS | $28,580 | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | 2025 |
| 2025-04-28 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $4,289 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-04-24 | Eli Lilly Export S.A. Puerto Rico Branch | VELOCITY CLINICAL RESEARCH INC | $7,813 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PART | 2025 |
| 2025-04-15 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $4,024 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-04-08 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $4,331 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO | 2025 |
| 2025-03-21 | Shionogi Inc | VELOCITY CLINICAL RESEARCH INC | $17,702 | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Effica | 2025 |
| 2025-02-25 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $14,500 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-02-25 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $2,400 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-02-25 | F. Hoffmann-La Roche AG | VELOCITY CLINICAL RESEARCH INC | $4,500 | CT-388-104 OW/OB with T2D | 2025 |
| 2025-02-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $730 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $58 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $6 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $209 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $139 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-21 | AstraZeneca Pharmaceuticals LP | Velocity Clinical Research | $10,149 | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat i | 2025 |
| 2025-02-10 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $22,503 | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2025 |
| 2025-01-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $465 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $360 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $1,197 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $150 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $260 | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $239 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $2 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $3 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $21 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $5 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $12 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $4 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-30 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $4 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-01-13 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $31,109 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-08 | Eli Lilly and Company | DALLAS DIABETES AND ENDO RESEARCH CENTER PA | $2,235 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-07 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $23,541 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-07 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $134,461 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-07 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $96,966 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 |
| 2025-01-06 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $144,468 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | VELOCITY CLINICAL RESEARCH DALLAS | $145,664 | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety o | 2025 |
| 2024-12-31 | Medtronic, Inc. | Velocity Clinical Research | $1,052 | CIP341 IMPACT2 | 2024 |
| 2024-11-29 | Eli Lilly and Company | Cedars-Sinai Medical Center | $130 | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2024 |
| 2024-11-29 | Eli Lilly and Company | Cedars-Sinai Medical Center | $130 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 |
| 2024-11-25 | Boehringer Ingelheim International GmbH | VELOCITY CLINICAL RESEARCH DALLAS | $21,000 | BI 456906 in NASH F2/F3 - pivotal trial | 2024 |
| 2024-10-31 | Eli Lilly and Company | Cedars-Sinai Medical Center | $90 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-10-31 | Eli Lilly and Company | Cedars-Sinai Medical Center | $195 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-10-01 | VERTEX PHARMACEUTICALS INCORPORATED | VELOCITY CLINICAL RESEARCH DALLAS | $22,291 | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety o | 2024 |
| 2024-10-01 | Eli Lilly and Company | Cedars-Sinai Medical Center | $6,340 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-07-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $60 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-07-31 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $214 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-07-16 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $81,942 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-06-30 | Medtronic, Inc. | Velocity Clinical Research | $14,370 | CIP341 IMPACT2 | 2024 |
| 2024-06-14 | AstraZeneca Pharmaceuticals LP | Velocity Clinical Research | $16,499 | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat i | 2024 |
| 2024-05-06 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $316 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-04-30 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $390 | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2024 |
| 2024-04-29 | Eli Lilly and Company | VELOCITY CLINICAL RESEARCH INC | $16,480 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rockwall, TX, county Rockwall County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Rockwall, TX | County Rockwall County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 51,168 | 123,617 | 30,188,424 |
| Population, 2020 census P1 | 47,251 | 107,819 | 29,145,505 |
| Median age B01002 | 39.5 | 37.5 | 35.6 |
| Under 18 B01001 | 24.3% | 26.5% | 25.0% |
| 65 and over B01001 | 15.8% | 12.6% | 13.4% |
| Households B11001 | 18,273 | 41,237 | 10,992,816 |
| Foreign born B05002 | 9.7% | 8.9% | 17.6% |
| Median household income B19013 | $115,580 | $127,981 | $78,476 |
| Median family income B19113 | $136,652 | $141,391 | $94,599 |
| Per capita income B19301 | $52,156 | $55,374 | $40,752 |
| Poverty rate B17001 | 4.0% | 4.0% | 13.8% |
| Unemployment rate B23025 | 4.4% | 4.3% | 5.3% |
| Civilian labor force B23025 | 27,787 | 66,399 | 15,233,563 |
| Mean commute (minutes) B08013 | 31.8 | 33.8 | 26.7 |
| Bachelor's degree or higher B15003 | 48.6% | 44.5% | 33.8% |
| Housing units B25001 | 19,328 | 43,580 | 12,128,515 |
| Owner-occupied B25003 | 72.5% | 82.5% | 62.6% |
| Renters B25003 | 27.5% | 17.5% | 37.4% |
| Median home value B25077 | $411,700 | $415,500 | $283,800 |
| Median gross rent B25064 | $1,947 | $1,992 | $1,403 |
| White, not Hispanic B03002 | 65.3% | 63.0% | 39.1% |
| Black B03002 | 10.8% | 9.1% | 11.9% |
| Hispanic or Latino B03002 | 15.8% | 20.8% | 39.7% |
| Asian B03002 | 4.6% | 3.5% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rockwall, TX.
Comments